SIRPA and neoplasm: The use of SIRPαFc (TTI-621), a decoy receptor that blocks the interaction of CD47 with SIRPα, was shown to provide a therapeutic benefit to patients with SS by significantly reducing the tumor load through the inhibition of the CD47-SIRPα signaling pathway in a clinical trial (NCT02663518).